Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02923986
Title Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bio-Path Holdings, Inc.

chronic myeloid leukemia

acute myeloid leukemia

myelodysplastic syndrome


BP1001 + Dasatinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.